Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase I trial tests the safety, best dose, and effectiveness of ZEN003694 in combination with cetuximab and encorafenib in treating patients with colorectal cancer that has not responded to previous treatment (refractory), that has come back after a period of improvement (relapsed), and that has spread from where it first started (primary site) to other places in the body (metastatic). ZEN003694 is a protein inhibitor that binds to BET proteins. When ZEN003694 binds to BET proteins, it disrupts gene expression. Preventing the expression of certain growth-promoting genes may inhibit proliferation of tumor cells that over-express BET proteins. Immunotherapy with monoclonal antibodies, such as cetuximab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Encorafenib is an enzyme inhibitor. It inhibits pathways that are responsible for controlling cell proliferation and survival, which may lead to a decrease in tumor cell proliferation. Both cetuximab and encorafenib have been approved to treat cancer. Adding ZEN003694 to cetuximab and encorafenib may be more effective at treating patients with refractory metastatic colorectal cancer than giving the usual treatment (cetuximab and encorafenib) alone.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rak jelita grubego, który rozprzestrzeniył się na inne części ciała, z mutacją genetyczną BRAF V600E
- •Wiek co najmniej 18 lat
- •Ogólny stan zdrowia umożliwiający leczenie (wynik ECOG 0-2)
- •Wystarczająca liczba białych krwinek (neutrofile ≥ 1500/mcL)
- •Wystarczająca liczba płytek krwi (≥ 100 000/mcL)
- •Hemoglobina co najmniej 9 mg/dl
- •Prawidłowe funkcje wątroby i nerek
- •Pacjenci z HIV lub zapaleniem wątroby mogą uczestniczyć, jeśli są skutecznie leczeni
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 23, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (16)
UC Irvine Health Cancer Center-Newport
Costa Mesa, United States
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, United States
Los Angeles General Medical Center
Los Angeles, United States
USC / Norris Comprehensive Cancer Center
Los Angeles, United States
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, United States
UCHealth University of Colorado Hospital
Aurora, United States
University of Kansas Clinical Research Center
Fairway, United States
University of Kansas Cancer Center
Kansas City, United States
University of Kansas Hospital-Indian Creek Campus
Overland Park, United States
University of Kansas Hospital-Westwood Cancer Center
Westwood, United States
Ochsner Medical Center Jefferson
New Orleans, United States
Ohio State University Comprehensive Cancer Center
Columbus, United States
University of Oklahoma Health Sciences Center
Oklahoma City, United States
UT MD Anderson Cancer Center
Houston, United States
University of Virginia Cancer Center
Charlottesville, United States
VCU Massey Comprehensive Cancer Center
Richmond, United States
Trial contact
Site Public Contact
Farshid Dayyani
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Heinz-Josef Lenz
PRINCIPAL_INVESTIGATOR
Site Public Contact
Alexis D. Leal
PRINCIPAL_INVESTIGATOR
Site Public Contact
Shafia Rahman
PRINCIPAL_INVESTIGATOR
Site Public Contact
Susanna V. Ulahannan
PRINCIPAL_INVESTIGATOR
Site Public Contact
Salvador Alonso Martinez
PRINCIPAL_INVESTIGATOR
Site Public Contact
Paul Kunk
PRINCIPAL_INVESTIGATOR
Site Public Contact
Khalid Matin
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/11/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.